Please login to the form below

Not currently logged in
Email:
Password:

major depressive disorder

This page shows the latest major depressive disorder news and features for those working in and with pharma, biotech and healthcare.

Janssen submits esketamine in Europe for treatment resistant depression

Janssen submits esketamine in Europe for treatment resistant depression

Esketamine is a glutamate receptor modulator, for treatment-resistant depression (TRD) in adults with Major Depressive Disorder (MDD). ... Mathai Mammen. “Major Depressive Disorder affects approximately 40 million people across Europe, and is the

Latest news

  • Sage surges after depression drug gets rapid path to approval Sage surges after depression drug gets rapid path to approval

    SAGE-217 is being tested in post-partum depression (PPD) that affects mother after childbirth as well as major depressive disorder (MDD), for which Sage reported positive phase 2 results last ... SAGE-217, if successfully developed and approved, may

  • Daily Brief Daily Brief

    With about 30% of patients with major depression failing to respond to currently available antidepressants1, treatment-resistant depression represents a major public health need," said Husseini K. ... Esketamine received Breakthrough Therapy Designations

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    Despite a clinical efficacy and safety package with data from more than 30 clinical trials and around 1, 500 patients with major depressive disorder (MDD), the FDA has said it wants

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    First approved in 2015, Rexulti is currently available as an adjunctive therapy for adults with major depressive disorder as well as for schizophrenia and after a slow start, has seen its ... Abilify. Lundbeck and Otsuka are also evaluating the drug in a

  • FDA approves first substance use mobile medical application FDA approves first substance use mobile medical application

    More therapy tools means a greater potential to help improve outcomes, including abstinence, for patients with substance use disorder.”. ... However, Pear’s development pipeline does include a version of the app specifically for opioid use disorder,

More from news
Approximately 6 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    condition and the promise of major therapeutic breakthroughs. ... major depressive disorder and iron-deficiency anaemia.

  • Pharma deals continue to slide Pharma deals continue to slide

    74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase II oral kappa opioid receptor antagonist for adjunctive treatment of major depressive disorder.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics